Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Why Does the World Continue to Struggle with Preventable Patient Harm?

Patient safety is something every healthcare organization wants to improve upon, especially with the shift to value-based care. However, most are missing the mark with preventable patient harm and truly being patient-centric. Discussing the topic today, B2B Today host Daniel Litwin spoke with Dr. Donna Prosser, Chief Clinical Officer of the Patient Safety Movement Foundation, a nonprofit…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Patient safety is something every healthcare organization wants to improve upon, especially with the shift to value-based care. However, most are missing the mark with preventable patient harm and truly being patient-centric. Discussing the topic today, B2B Today host Daniel Litwin spoke with Dr. Donna Prosser, Chief Clinical Officer of the Patient Safety Movement Foundation, a nonprofit that’s goal to reach zero preventable patient harm and deaths. The company will host the #UniteForSafeCare event on World Patient Day on September 17.

“There had been success in improving patient safety, but that fell apart during COVID because there was a hyper-focus. It comes down to the lack of a high-reliability foundation,” Dr. Prosser noted.

“Hospitals are businesses and concerned about public image and marketability. That sustains a culture of silence where no one talks about the issues.” – Dr. Donna Prosser

Dr. Prosser argued that while organizations say they are patient-focused, the processes and structure of healthcare is clinician-focused. That could be why some clinicians seem to make numerous errors undetected, as seen in the upcoming TV show Dr. Death, which centers on a real neurosurgeon’s medical incompetence.

“This is at the far end of the spectrum, but other situations happen regularly because of the way the system is set up. Transparency, openness, and trust aren’t there. People saw this behavior and didn’t feel comfortable voicing it or hit a wall if they did,” Dr. Prosser explained.

This “culture of silence” is what perpetuates preventable patient harm. That’s reflected in research. One survey found that 6% of patients were affected, while another from the World Health Organization (WHO) found that four in 10 patients suffered some harm.

So, what’s the answer to address preventable harm? Dr. Prosser said, “No one can do it alone. All stakeholders have to be at the table. We have to band together, shine a light on it, address it, and create those highly reliable systems. It will require culture change.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512